MX2022003885A - Receptores quimericos de citoquinas. - Google Patents
Receptores quimericos de citoquinas.Info
- Publication number
- MX2022003885A MX2022003885A MX2022003885A MX2022003885A MX2022003885A MX 2022003885 A MX2022003885 A MX 2022003885A MX 2022003885 A MX2022003885 A MX 2022003885A MX 2022003885 A MX2022003885 A MX 2022003885A MX 2022003885 A MX2022003885 A MX 2022003885A
- Authority
- MX
- Mexico
- Prior art keywords
- cytokine receptors
- cells
- chimeric cytokine
- receptors
- selective activation
- Prior art date
Links
- 102000003675 cytokine receptors Human genes 0.000 title abstract 2
- 108010057085 cytokine receptors Proteins 0.000 title abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 108700010039 chimeric receptor Proteins 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464418—Receptors for colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
Abstract
En el presente documento se describen receptores quiméricos que comprenden dominios extracelulares de G-CSFR y los dominios intracelulares de varios receptores de citocinas de múltiples subunidades para la activación selectiva de la señalización de citocinas en las células de interés. En determinados aspectos, la activación selectiva de la señalización de citocinas en las células que expresan los receptores quiméricos descritos en el presente documento, incluye la capacidad de estimular específicamente las células transferidas adoptivamente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962912223P | 2019-10-08 | 2019-10-08 | |
PCT/CA2020/051346 WO2021068068A1 (en) | 2019-10-08 | 2020-10-08 | Chimeric cytokine receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003885A true MX2022003885A (es) | 2022-07-13 |
Family
ID=75436949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003885A MX2022003885A (es) | 2019-10-08 | 2020-10-08 | Receptores quimericos de citoquinas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240122979A1 (es) |
EP (1) | EP4041893A4 (es) |
JP (1) | JP2022552949A (es) |
KR (1) | KR20220108768A (es) |
CN (1) | CN114929752A (es) |
AU (1) | AU2020362554A1 (es) |
BR (1) | BR112022006782A2 (es) |
CA (1) | CA3151472A1 (es) |
IL (1) | IL291282A (es) |
MX (1) | MX2022003885A (es) |
WO (1) | WO2021068068A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024515577A (ja) * | 2021-04-07 | 2024-04-10 | プロヴィンシャル ヘルス サービシーズ オーソリティ | 修飾された顆粒球コロニー刺激因子(g-csf)及びこれに結合するキメラサイトカイン受容体 |
WO2024015734A1 (en) * | 2022-07-11 | 2024-01-18 | Sonoma Biotherapeutics, Inc. | Recombinant cytokine receptors and methods of use |
WO2024044768A2 (en) * | 2022-08-26 | 2024-02-29 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric cytokine receptors and methods of use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2160011A1 (en) * | 1993-04-06 | 1994-10-13 | Philip D. Greenberg | Chimeric cytokine receptors in lymphocytes |
JP6450690B2 (ja) * | 2013-02-15 | 2019-01-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | キメラ抗原受容体及びその使用方法 |
KR101962524B1 (ko) * | 2013-11-21 | 2019-07-17 | 유씨엘 비즈니스 피엘씨 | 세포 |
JP7125351B2 (ja) * | 2016-04-14 | 2022-08-24 | 2セブンティ バイオ インコーポレイテッド | サルベージキメラ抗原受容体システム |
JP2022553152A (ja) * | 2019-10-08 | 2022-12-22 | ザイムワークス,インコーポレイテッド | 顆粒球コロニー刺激因子受容体(g-csfr)の改変された細胞外ドメイン及びそれに結合するサイトカイン |
-
2020
- 2020-10-08 WO PCT/CA2020/051346 patent/WO2021068068A1/en unknown
- 2020-10-08 US US17/767,687 patent/US20240122979A1/en active Pending
- 2020-10-08 CN CN202080084817.5A patent/CN114929752A/zh active Pending
- 2020-10-08 JP JP2022521201A patent/JP2022552949A/ja active Pending
- 2020-10-08 CA CA3151472A patent/CA3151472A1/en active Pending
- 2020-10-08 AU AU2020362554A patent/AU2020362554A1/en active Pending
- 2020-10-08 BR BR112022006782A patent/BR112022006782A2/pt unknown
- 2020-10-08 KR KR1020227015391A patent/KR20220108768A/ko unknown
- 2020-10-08 EP EP20873827.8A patent/EP4041893A4/en active Pending
- 2020-10-08 MX MX2022003885A patent/MX2022003885A/es unknown
-
2022
- 2022-03-10 IL IL291282A patent/IL291282A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3151472A1 (en) | 2021-04-15 |
BR112022006782A2 (pt) | 2022-09-06 |
IL291282A (en) | 2022-05-01 |
US20240122979A1 (en) | 2024-04-18 |
CN114929752A (zh) | 2022-08-19 |
EP4041893A1 (en) | 2022-08-17 |
KR20220108768A (ko) | 2022-08-03 |
JP2022552949A (ja) | 2022-12-21 |
EP4041893A4 (en) | 2023-08-30 |
WO2021068068A1 (en) | 2021-04-15 |
AU2020362554A1 (en) | 2022-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003885A (es) | Receptores quimericos de citoquinas. | |
MX2018005618A (es) | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. | |
MX2019003899A (es) | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. | |
MY190404A (en) | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling | |
SA518400135B1 (ar) | T مولد ضد خيمري ومستقبلات خلية وطرق استخدامها | |
MX2019006374A (es) | Receptores inmunes sinteticos y metodos de usos de ellos. | |
MX2018000278A (es) | Terapia de receptores quimericos de puntos de control inmunitarios. | |
EP3600356A4 (en) | ABBREVIATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS | |
EA202091342A3 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
MX2020013977A (es) | Proteínas quiméricas transmembrana y usos de las mismas. | |
MX2020010241A (es) | Composiciones de inmunoterapia celular y usos de las mismas. | |
MX2021010809A (es) | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. | |
PH12015502438A1 (en) | Compositions and methods for activating ``stimulator of interferon gene``-dependent signalling | |
MX2018005299A (es) | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon". | |
MY194328A (en) | Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use | |
MX2019001223A (es) | Moduladores de receptores de quimioquina y usos de los mismos. | |
WO2017201432A3 (en) | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity | |
MX2015011408A (es) | Antagonistas de il-33 y usos de estos. | |
MX2019015349A (es) | Anticuerpos biespecificos para receptor 1 huerfano tipo receptor de tirosina cinasa (ror1) y grupo de diferenciacion 3 (cd3). | |
WO2014055413A3 (en) | A method of providing cellular therapy using modified natural killer cells or t lymphocytes | |
PH12021550764A1 (en) | Trem2 stabilizing antibodies | |
MX364107B (es) | Sistema de suministro para agentes activos. | |
MX360097B (es) | Agonistas y antagonistas del receptor tipo i de il-1 quimérico. | |
EP3749685A4 (en) | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY | |
MX2021005593A (es) | Miméticos de interleucina dividida y sus usos. |